The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis

BACKGROUND: Anemia is considered a negative prognostic risk factor for survival in patients with myelofibrosis. Most patients with myelofibrosis are anemic, and 35–54 % present with anemia at diagnosis. Ruxolitinib, a potent inhibitor of Janus kinase (JAK) 1 and JAK2, was associated with an overall...

Descripción completa

Detalles Bibliográficos
Autores principales: McMullin, Mary Frances, Harrison, Claire N., Niederwieser, Dietger, Demuynck, Hilde, Jäkel, Nadja, Gopalakrishna, Prashanth, McQuitty, Mari, Stalbovskaya, Viktoriya, Recher, Christian, Theunissen, Koen, Gisslinger, Heinz, Kiladjian, Jean-Jacques, Al-Ali, Haifa-Kathrin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570722/
https://www.ncbi.nlm.nih.gov/pubmed/26380150
http://dx.doi.org/10.1186/s40164-015-0021-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570722/
https://www.ncbi.nlm.nih.gov/pubmed/26380150
http://dx.doi.org/10.1186/s40164-015-0021-2

Ejemplares similares